Ahmed Koriesh/LinkedIn
Mar 27, 2026, 17:19
Ahmed Koriesh: Would You Start DAPT If the Patient Presents After 24 Hours?
Ahmed Koriesh, Director of Hospital Neurology Service at Cleveland Clinic Florida, shared on LinkedIn:
”Would you start DAPT if the patient presents after 24 hours?
Yes — why not.
The key concept
- Stroke recurrence risk is front-loaded.
- Highest risk in the first 3–7 days
- Then declines significantly
When you look at recurrence curves:
Steep early rise to gradual flattening
Why this matters
- Early phase equals unstable plaque, high embolic risk
- This is where DAPT has the greatest impact
Practical take
- <24h: ideal (trial-based)
- 24h – several days: still meaningful benefit
- Approxmately 1 week: diminishing returns
There is no sharp cutoff — it’s a gradient, not a binary window
What about the Trials?
- Trials (CHANCE/POINT) used ≤24h to maximize efficacy
- But biology doesn’t stop at 24h
- Risk – and potential benefit – persists beyond that
Bottom line
If patient present with minor stroke after 24h, still within few days, would still benefit from DAPT to reduce recurrence, specially in high risk patients.”

Stay updated with Hemostasis Today.
-
Mar 27, 2026, 17:17Ifeanyichukwu Ifechidere: Understanding the Sensitivity and Specificity of D-Dimer
-
Mar 27, 2026, 17:15Wolfgang Miesbach: The Benefit with Hemophilia Rebalancing Agents Is Real, But So Are The Open Questions
-
Mar 27, 2026, 17:13Sheharyar Raza: Applying AI to Accelerate Big Data Research in Transfusion Medicine
-
Mar 27, 2026, 17:09Caitlin Raymond: Jehovah’s Witnesses May Now Accept Autologous Blood
-
Mar 27, 2026, 17:06Tareq Abadl: The Importance of CBC Analysis in Detecting Lupus Activity
-
Mar 27, 2026, 17:03Louise St. Germain Bannon: Making Adherence Easier, More Human and More Achievable for Everyone on World Adherence Day
-
Mar 27, 2026, 16:58Promising Thrombin Biomarkers For Identifying High-Risk VTE Patients – JTH
-
Mar 27, 2026, 16:53Brecca Gaffney: The Role of Hemophilia Severity on Movement Patterns
-
Mar 27, 2026, 16:46Anita Brikman: Expanding Access to Plasma-Derived Medicines in India